Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Beijing Tuobixi Pharmaceutical
Beijing, Beijing, Chinabeijingtuojie.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Beijing Tuojie Biomedical Technology specializes in therapeutic proteins, peptide biopharmaceuticals, and stem cell drugs targeting chronic conditions such as metabolic, cardiovascular, nervous system diseases, and osteoarthritis. Its lead candidate BJTJ‑0003 is a bio-fermented monoclonal antibody in Phase 2 clinical trials for thrombosis.
- Therapeutic areas
- RheumatologyMetabolic DisordersCardiovascularNeurology
- Modalities
- Monoclonal antibodySmall moleculeRecombinant polypeptideSynthetic peptideFusion protein
- Industry
- Biotech
Beyond the preview
Go deeper on Beijing Tuobixi Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Beijing Tuobixi Pharmaceutical.